Tehran University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
A Decline in Anti-Core+1 Antibody Titer Occurs in Successful Treatment of Patients Infected With Hepatitis C Virus Publisher



Hashempoor T1, 2 ; Alborzi AM3 ; Moayedi J1, 4 ; Ajorloo M5 ; Bamdad T6 ; Sharifi AH2 ; Lavergne JP7 ; Hajsheykholeslami A2 ; Merat S2
Authors
Show Affiliations
Authors Affiliations
  1. 1. Shiraz HIV/AIDS Research Center, Institute of Health, Shiraz University of Medical Sciences, Shiraz, Iran
  2. 2. Liver and Pancreatobiliary Diseases Research Center, Digestive Diseases Research Institute, Tehran University of Medical Sciences, Tehran, Iran
  3. 3. Cancer Research Center of Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran
  4. 4. Comparative Biomedical Research Center, Shiraz University of Medical Sciences, Shiraz, Iran
  5. 5. Hepatitis Research Center, Lorestan University of Medical Sciences, Khorramabad, Iran
  6. 6. Department of Virology, Faculty of Medical Sciences, Tarbiat Modares University, Tehran, Iran
  7. 7. Laboratoire de Bioinformatique et RMN structurales, Institut de Biologie et Chimie des proteines, UMR 5086 CNRS, Universite Claude Bernard Lyon I, Lyon, France

Source: Jundishapur Journal of Microbiology Published:2018


Abstract

Background: Hepatitis C virus (HCV) causes one of the major chronic liver diseases (CLD). Hepatitis C virus- core encoding sequence possesses an overlapping open reading frame (ORF) that expresses a protein called F or core+1. Objectives: The current study aimed at assessing the presence and titer of anti-core+1 antibody (Ab) in 70 Iranian patients infected with HCV-1a, responder and non-responder groups, under combination therapy with pegylated interferon-α (PegIFN-α) plus ribavirin (RBV) using an enzyme-linked immunosorbent assay (ELISA). Methods: In the current cohort study, HCV-1a core+1 gene was amplified and cloned into vector followed by expressing in Escherichia coli and then, purified by ion exchange chromatography. The antibody titer of patients was evaluated before, during (12, 24, and 48 weeks), and 6 months after the end of therapy (ETR). Results: The seroprevalence of anti-core+1 Ab was 75.7% in pretreatment sera. The combination therapy could induce a decline in the level of anti-core+1 Ab in both groups of responders and non-responders. These changes were significant only in the responders (P = 0.003). The seroprevalence of anti-core+1 Ab had no correlation with the outcome of treatment. Conclusions: According to the current study results, HCV core+1 protein elicit a specific antibody response other than the anti-core protein antibodies. The current study data also suggested that the level of anti-core+1 antibodymightbeaffected by the combination therapyandassociated with sustained virological response (SVR). The data implied that the declining trend of anti-core+1 Abs during the treatment might be an alternative representation of the therapeutic response in Iranian population infected with HCV. © 2018, Jundishapur Journal of Microbiology.
Related Docs
1. Antibody Development to Hcv Alternate Reading Frame Protein in Liver Transplant Candidate and Its Computational Analysis, Current Proteomics (2020)
2. Detection of Specific Antibodies to Hcv-Arf/Core+1 Protein in Cirrhotic and Non-Cirrhotic Patients With Hepatitis C: A Possible Association With Progressive Fibrosis, Archives of Iranian Medicine (2015)
3. The Predictive Factors for Favorable Outcomes of Peginterferon and Ribavirin Combination Therapy in Hcv-Infected Patients, Acta Medica Iranica (2020)
4. F Protein Increases Cd4+Cd25+ T Cell Population in Patients With Chronic Hepatitis C, Pathogens and Disease (2015)
5. Impact of Il28 Genotypes and Modeling the Interactions of Hcv Core Protein on Treatment of Hepatitis C, Interdisciplinary Sciences – Computational Life Sciences (2020)